Xencor (XNCR) Intangibles (2013 - 2026)
Xencor (XNCR) posted quarterly Intangibles of $7.6 million for Q1 2026, down 43.11% year-over-year from $13.4 million in Q1 2025, and down 9.34% quarter-over-quarter from $8.4 million in Q4 2025.
Xencor (XNCR) Intangibles (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Intangibles for 14 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 43.11% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 43.11% YoY), while the FY2025 annual figure was $8.4 million, down 54.64% from the prior year.
- Intangibles eased to $7.6 million in Q1 2026 per XNCR's latest filing, from $8.4 million in the prior quarter.
- Across five years, Intangibles topped out at $18.9 million in Q1 2024 and bottomed at $7.6 million in Q1 2026.
- Historically, Intangibles has averaged $15.9 million across 5 years, with a median of $18.1 million in 2022.
- Annual changes were most pronounced in 2022 — Intangibles climbed 12.17% — and 2025, when it sank 54.64%.
- Xencor's Intangibles stood at $18.5 million in 2022, then climbed by 0.88% to $18.7 million in 2023, then retreated by 0.95% to $18.5 million in 2024, then tumbled by 54.64% to $8.4 million in 2025, then decreased by 9.34% to $7.6 million in 2026.
- Business Quant data shows XNCR's Intangibles at $7.6 million in Q1 2026, $8.4 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 6.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.52 Mn |
| Mar 31, 2026 | 7.60 Mn |
| Dec 31, 2025 | 8.39 Mn |
| Sep 30, 2025 | 9.47 Mn |
| Jun 30, 2025 | 11.25 Mn |
| Mar 31, 2025 | 13.36 Mn |
| Dec 31, 2024 | 18.49 Mn |
| Sep 30, 2024 | 17.92 Mn |
| Jun 30, 2024 | 18.78 Mn |
| Mar 31, 2024 | 18.85 Mn |
| Dec 31, 2023 | 18.66 Mn |
| Sep 30, 2023 | 18.74 Mn |
| Jun 30, 2023 | 18.71 Mn |
| Mar 31, 2023 | 18.24 Mn |
| Dec 31, 2022 | 18.50 Mn |
| Sep 30, 2022 | 18.09 Mn |
| Jun 30, 2022 | 17.94 Mn |
| Mar 31, 2022 | 16.71 Mn |
| Dec 31, 2021 | 16.49 Mn |
| Sep 30, 2021 | 16.68 Mn |